Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Gattaca delivers 'robust' H1 performance

(Sharecast News) - Staffing business Gattaca said on Thursday that it had delivered a "robust performance" in the six months ended 31 January, in line with expectations. Gattaca said group net fee income had decreased 3% year-on-year at £18.8m, with contract NFI 1% lower and permanent NFI dropping 10% year-on-year. Statement of work NFI was also down 3% year-on-year, as new client acquisitions partially offset delays linked to the public sector spend review.

The AIM-listed group also noted that it expects to report statutory net cash of £16.7m, down from of £22.3m a year earlier primarily due to a reduction in trade creditors.

Looking forward, Gattaca said group guidance for FY25 adjusted pre-tax profits remained at £3.0m and stated that it also expects to announce an interim dividend at its H1 results on 2 April.

Chief executive Matthew Wragg said: "Our strategic investments in growth opportunities are delivering positive momentum and our other sectors are proving resilient. The group continues to operate in a tough market environment, however with targeted investments in core sectors we remain focused on delivering long-term growth.

"We are confident that we will navigate the current conditions through strong engagement, high productivity, operational efficiency and active management of the group's cost base.

As of 1030, Gattaca shares had rallied 8.04% to 77.25p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.